Michael Walsh

24.0k total citations · 7 hit papers
158 papers, 11.2k citations indexed

About

Michael Walsh is a scholar working on Nephrology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael Walsh has authored 158 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Nephrology, 54 papers in Pulmonary and Respiratory Medicine and 33 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael Walsh's work include Vasculitis and related conditions (40 papers), Dialysis and Renal Disease Management (29 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (29 papers). Michael Walsh is often cited by papers focused on Vasculitis and related conditions (40 papers), Dialysis and Renal Disease Management (29 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (29 papers). Michael Walsh collaborates with scholars based in Canada, United States and United Kingdom. Michael Walsh's co-authors include P.J. Devereaux, David Jayne, Lehana Thabane, Gordon Guyatt, Kerstin Westman, Braden Manns, Amit X. Garg, Raashid Luqmani, Marcello Tonelli and Vladimı́r Tesař and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Michael Walsh

151 papers receiving 10.9k citations

Hit Papers

Rituximab versus Cyclophosphamide in ANCA-Associated Rena... 2007 2026 2013 2019 2010 2017 2013 2010 2007 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
    2010 1.1k citations Rachel Jones, Jan Willem Cohen Tervaert et al. profile →
  2. Discrimination and Calibration of Clinical Prediction Models
    2017 1.0k citations Michael Walsh, P.J. Devereaux et al. profile →
  3. Relationship between Intraoperative Mean Arterial Pressure and Clinical Outcomes after Noncardiac Surgery
    2013 922 citations Michael Walsh, P.J. Devereaux et al. Anesthesiology profile →
  4. Long-term patient survival in ANCA-associated vasculitis
    2010 641 citations David Jayne, Raashid Luqmani et al. Annals of the Rheumatic Diseases profile →
  5. Effect of Frequent Nocturnal Hemodialysis vs Conventional Hemodialysis on Left Ventricular Mass and Quality of Life
    2007 496 citations Michael Walsh, Marcello Tonelli et al. profile →
  6. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index
    2014 443 citations Michael Walsh, Marko Mrkobrada et al. Journal of Clinical Epidemiology profile →
  7. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses
    2020 356 citations Michael Walsh, Lehana Thabane et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Walsh Canada 45 4.6k 2.9k 2.4k 2.2k 1.9k 158 11.2k
Myles Wolf United States 75 2.5k 0.6× 13.6k 4.7× 2.6k 1.1× 1.3k 0.6× 1.7k 0.9× 247 22.6k
Beverley J. Hunt United Kingdom 65 1.7k 0.4× 1.5k 0.5× 4.7k 2.0× 2.8k 1.3× 3.4k 1.8× 340 19.3k
Jai Radhakrishnan United States 49 2.0k 0.4× 4.5k 1.6× 1.5k 0.6× 947 0.4× 528 0.3× 191 9.1k
David Goldsmith United Kingdom 62 2.0k 0.4× 5.1k 1.8× 1.8k 0.8× 449 0.2× 2.6k 1.4× 359 11.2k
Mary B. Leonard United States 65 1.4k 0.3× 4.5k 1.6× 2.6k 1.1× 1.1k 0.5× 667 0.4× 283 15.0k
Peter G. Kerr Australia 53 1.7k 0.4× 6.2k 2.2× 1.6k 0.7× 535 0.2× 1.3k 0.7× 256 10.4k
L. Jacobsson Sweden 58 1.2k 0.3× 1.4k 0.5× 1.8k 0.8× 6.8k 3.1× 722 0.4× 358 13.5k
Matthew J. Grainge United Kingdom 51 1.0k 0.2× 1.7k 0.6× 1.9k 0.8× 2.1k 1.0× 1.0k 0.6× 152 11.2k
Robert N. Foley United States 70 4.1k 0.9× 11.9k 4.1× 3.7k 1.6× 521 0.2× 5.4k 2.8× 199 19.6k
J. Michael Lazarus United States 62 2.6k 0.6× 10.0k 3.5× 2.9k 1.2× 428 0.2× 2.1k 1.1× 200 14.9k

Countries citing papers authored by Michael Walsh

Since Specialization
Citations

This map shows the geographic impact of Michael Walsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Walsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Walsh more than expected).

Fields of papers citing papers by Michael Walsh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Walsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Walsh. The network helps show where Michael Walsh may publish in the future.

Co-authorship network of co-authors of Michael Walsh

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Walsh. A scholar is included among the top collaborators of Michael Walsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Walsh. Michael Walsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Misra, Durga Prasanna, et al.. (2025). The fragility of randomized controlled trials in large vessel vasculitis. Autoimmunity Reviews. 24(12). 103917–103917. 1 indexed citations
3.
Smyth, Andrew, Amber O. Molnar, Paul Moayyedi, et al.. (2024). The Effects of Pantoprazole on Kidney Outcomes. Journal of the American Society of Nephrology. 35(7). 901–909. 2 indexed citations
4.
Odler, Balazs, Regina Riedl, Duvuru Geetha, et al.. (2024). The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial. Kidney International. 107(3). 558–567. 3 indexed citations
5.
Winkelmayer­, Wolfgang C., Anthonie W.A. Lensing, Ravi Thadhani, et al.. (2024). A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney International. 106(1). 145–153. 16 indexed citations
6.
Xiao, Yingqi, Gordon Guyatt, Linan Zeng, et al.. (2022). Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open. 12(2). e050507–e050507. 13 indexed citations
7.
Devji, Tahira, Anila Qasim, Qiukui Hao, et al.. (2021). A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. Journal of Clinical Epidemiology. 142. 144–151. 15 indexed citations
8.
Collister, David, Jeff S. Healey, David Conen, et al.. (2019). Canadian Nephrologist Views Regarding Stroke and Systemic Embolism Prevention in Dialysis Patients With Nonvalvular Atrial Fibrillation: A Survey. Canadian Journal of Kidney Health and Disease. 6. 2246701113–2246701113. 3 indexed citations
9.
Pai, Menaka, Neill K. J. Adhikari, Marlies Ostermann, et al.. (2018). Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. PLoS ONE. 13(6). e0198285–e0198285. 12 indexed citations
10.
Sjaarda, Jennifer, Hertzel C. Gerstein, Salim Yusuf, et al.. (2018). Blood HER2 and Uromodulin as Causal Mediators of CKD. Journal of the American Society of Nephrology. 29(4). 1326–1335. 22 indexed citations
11.
Wald, Ron, Kevin E. Thorpe, & Michael Walsh. (2018). Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease. Current Opinion in Nephrology & Hypertension. 28(1). 34–39. 1 indexed citations
12.
13.
14.
Wald, Ron, Christian G. Rabbat, Louis Girard, et al.. (2017). Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clinical Journal of the American Society of Nephrology. 12(6). 965–973. 27 indexed citations
15.
Walsh, Michael, Braden Manns, Amit X. Garg, et al.. (2015). The Safety of Eplerenone in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology. 10(9). 1602–1608. 41 indexed citations
16.
Jones, Rachel, Shunsuke Furuta, Jan Willem Cohen Tervaert, et al.. (2015). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases. 74(6). 1178–1182. 185 indexed citations
17.
Walsh, Michael, P.J. Devereaux, Amit X. Garg, et al.. (2013). Relationship between Intraoperative Mean Arterial Pressure and Clinical Outcomes after Noncardiac Surgery. Anesthesiology. 119(3). 507–515. 922 indexed citations breakdown →
18.
Merkel, Peter A., Karen Herlyn, Alfred Mahr, et al.. (2009). Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. The Journal of Rheumatology. 36(10). 2362–2368. 32 indexed citations
19.
Walsh, Michael, Marcello Tonelli, David Jayne, & Braden Manns. (2007). Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. Journal of Nephrology. 20(2). 119–129. 3 indexed citations
20.
Walsh, Michael, Matthew T. James, David Jayne, et al.. (2007). Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis. Clinical Journal of the American Society of Nephrology. 2(5). 968–975. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Myles Wolf Breakdown of academic impact, for papers by Beverley J. Hunt Breakdown of academic impact, for papers by Jai Radhakrishnan Breakdown of academic impact, for papers by David Goldsmith Breakdown of academic impact, for papers by Mary B. Leonard Breakdown of academic impact, for papers by Peter G. Kerr Breakdown of academic impact, for papers by L. Jacobsson Breakdown of academic impact, for papers by Matthew J. Grainge Breakdown of academic impact, for papers by Robert N. Foley Breakdown of academic impact, for papers by J. Michael Lazarus
Rankless by CCL
2026